Harpoon Therapeutics is a biotechnology business based in the US. Harpoon Therapeutics shares (HARP) are listed on the NASDAQ and all prices are listed in US Dollars. Harpoon Therapeutics employs 53 staff and has a trailing 12-month revenue of around $37.3 million.
Become a Finder member, open a SoFi Active Invest account and make a first deposit of $1,000 or more to receive a $150 gift card. Offer ends March 4, 2026.
T&Cs and limits apply.
0588148b-2286-4b8f-9672-9c8cdafc0370-Get up to $1,000 in stock
Get up to $1,000 in stock
Trade stocks, options, ETFs, mutual funds, alternative asset funds
$0 commission on stocks, ETFs and options with no options contract fees
Get up to $1,000 in stock when you open & fund a new Active Invest account.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longerqualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link See full terms and For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Must be a SoFi Plus member at the time a recurring deposit is received into your SoFi Active or Automated investing account to qualify. Bonus calculated on net monthly recurring deposits made via ACH and paid out as Rewards Points. See Rewards Terms of Service. SoFi reserves the right to change or terminate this promotion at any time without notice. See terms and limitations. https://www.sofi.com/sofiplus/invest/#disclaimers
eToro securities trading offered by eToro USA Securities, Inc. (‘the BD”), member of FINRA and SIPC. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finder is not an affiliate and may be compensated if you access certain products or services offered by the BD.
d19c0be9-29b6-4644-a071-32c476ff5e24-Top pick for match bonus
Top pick for match bonus
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $100,000+ to earn a 4% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – HARP.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Harpoon Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Harpoon Therapeutics stock price (NASDAQ: HARP)
Use our graph to track the performance of HARP stocks over time.
Is it a good time to buy Harpoon Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Harpoon Therapeutics financials
Revenue TTM
$37.3 million
Gross profit TTM
$-49,478,000
Return on assets TTM
-35.66%
Return on equity TTM
-284.32%
Profit margin
-81.67%
Book value
$1.11
Market Capitalization
$492.3 million
TTM: trailing 12 months
Harpoon Therapeutics share dividends
We're not expecting Harpoon Therapeutics to pay a dividend over the next 12 months.
Have Harpoon Therapeutics's shares ever split?
Harpoon Therapeutics's shares were
split on a 1:10 basis on 4 September 2023
. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Harpoon Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Harpoon Therapeutics shares which in turn could have impacted Harpoon Therapeutics's share price.
Harpoon Therapeutics share price volatility
Over the last 12 months, Harpoon Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harpoon Therapeutics's is 2.098. This would suggest that Harpoon Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Harpoon Therapeutics overview
Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Frequently asked questions
null What percentage of Harpoon Therapeutics is owned by insiders or institutions? Currently 0.346% of Harpoon Therapeutics shares are held by insiders and 82.854% by institutions.How many people work for Harpoon Therapeutics? Latest data suggests 53 work at Harpoon Therapeutics.When does the fiscal year end for Harpoon Therapeutics? Harpoon Therapeutics's fiscal year ends in December.Where is Harpoon Therapeutics based? Harpoon Therapeutics's address is: 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080What is Harpoon Therapeutics's ISIN number? Harpoon Therapeutics's international securities identification number is: US41358P1066What is Harpoon Therapeutics's CUSIP number? Harpoon Therapeutics's Committee on Uniform Securities Identification Procedures number is: 41358P106
Discover the best stock picking services based on expert analysis, pricing, and strategy fit. Compare top tools to find the right service for your investing style in 2026.
Discover the best robo-advisors of 2026. Compare fees, account minimums and features from top platforms that automate investing for beginners and pros.
Vanguard is an investor-owned company that specializes in low-cost funds, but some fees and features lag the competition.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
